Kolexia
Hammel Pascal Gastro-entérologie
Hammel Pascal
Gastro-entérologie
Hôpital Paul Brousse
Villejuif, France
419 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du pancréas Adénocarcinome Carcinome du canal pancréatique Tumeurs neuroendocrines Carcinomes Métastase tumorale Pancréatite Récidive tumorale locale Tumeurs kystiques, mucineuses et séreuses

Collaborateurs

Voir plus
Ruszniewski Philippe
Ruszniewski Philippe
Hôpital Beaujon, Clichy, France
Cros Jerome
Cros Jerome
Hôpital Beaujon, Clichy, France
Bachet Jean Baptiste
Bachet Jean Baptiste
Hôpital Pitie Salpetriere, Paris, France
Hentic-Dhome Olivia
Hentic-Dhome Olivia
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Servier
22 collaboration(s)
Dernière en 2023
Mylan Medical
7 collaboration(s)
Dernière en 2020
Sanofi
5 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Pr Pascal Hammel / Solenne Besnard - Radio France
Radio France   11 mars 2024
MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients
Essai Clinique (AstraZeneca)   03 janvier 2024
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.
Journal of the National Comprehensive Cancer Network : JNCCN   16 décembre 2023
Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis
ESMO Gastrointestinal Oncology   01 décembre 2023
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   14 novembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
Adjuvant chemotherapy with gemcitabine plus erlotinib gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005.
Hepatobiliary surgery and nutrition   04 novembre 2023
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.
The lancet. Gastroenterology & hepatology   19 octobre 2023
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44): Two Arm, Prospective, Multicenter Randomized Phase II Trial of Neoadjuvant Modified Folfirinox Regimen, With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma
Essai Clinique (Institut de cancérologie de Lorraine)   26 septembre 2023
Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer: Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   26 septembre 2023